Stonepine Capital Management, LLC Viracta Therapeutics, Inc. Transaction History
Stonepine Capital Management, LLC
- $158 Billion
- Q3 2024
A detailed history of Stonepine Capital Management, LLC transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Stonepine Capital Management, LLC holds 500,000 shares of VIRX stock, worth $125,000. This represents 0.07% of its overall portfolio holdings.
Number of Shares
500,000Holding current value
$125,000% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding VIRX
# of Institutions
41Shares Held
5.63MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$380,0600.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA954KShares$238,6210.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$172,4270.09% of portfolio
-
Laurion Capital Management LP New York, NY332KShares$83,0470.0% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$72,1420.03% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $9.39M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...